Full-Time
Pharmaceutical company focused on dementia and oncology
No salary listed
Kansas City, MO, USA
In Person
Residence in Central Midwest (Missouri, Kansas, Nebraska, Iowa); field-based with ~60% travel; home-based office within territory.
PharmD, PhD, MD
Eisai is a Japanese research-based pharmaceutical company that discovers, develops, and markets prescription medicines under its "human health care (hhc)" concept. Its portfolio concentrates on neurology and oncology, including LEQEMBI (lecanemab), an anti-amyloid treatment for Alzheimer's disease now offered in intravenous and subcutaneous forms; lemborexant for insomnia; and the anticancer agent Halaven, developed through worldwide R&D and open-innovation partnerships. The company also runs a global health program that supplies medicines to more than 30 countries, having distributed billions of tablets to help eliminate neglected tropical diseases such as lymphatic filariasis. What sets Eisai apart is this hhc concept, which frames access and affordability—not only innovation—as central to its mission. The goal is to empower people to realize their fullest life by advancing treatments for conditions such as dementia and cancer.
Company Size
N/A
Company Stage
N/A
Total Funding
N/A
Headquarters
N/A
Founded
N/A
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Vision Insurance
Flexible Work Hours
Remote Work Options
Paid Vacation
Paid Holidays
401(k) Retirement Plan
401(k) Company Match
Wellness Program
Mental Health Support
Conference Attendance Budget
Professional Development Budget
Stock Options
Company Equity
Family Planning Benefits
Fertility Treatment Support
Adoption Assistance
Childcare Support
Tuition Reimbursement
Professional Certification Support
Mentorship Program
Remote Work Options
Home Office Stipend
Phone/Internet Stipend
FDA approves Takeda's first-in-class narcolepsy drug. Key summary: * FDA clears first drug to treat the underlying cause of narcolepsy type 1. * Takeda forecasts peak annual sales of up to $5bn for Orzeyful. * Rivals including Alkermes, Eli Lilly and Eisai are racing to develop competing therapies. Takeda has secured FDA approval for the first drug to treat the underlying cause of narcolepsy type 1, with the company forecasting peak annual sales of between $2bn and $3bn as it seeks further regulatory approvals. Known as Orzeyful (oveporexton), the therapy is an orexin receptor 2 agonist that restores a brain signal missing in people with narcolepsy type 1. Unlike existing treatments, it targets the underlying cause of the disease rather than simply treating its symptoms. Narcolepsy is a chronic neurological disorder characterised by excessive daytime sleepiness, sudden muscle weakness known as cataplexy, sleep paralysis and vivid hallucinations. For now, Orzeyful is approved only for adults with narcolepsy type 1 in the US. Its safety and efficacy have not yet been established in people younger than 18 years in the country. Orzeyful's efficacy. The approval was backed by positive results from two pivotal clinical trials. In the FirstLight and RadiantLight studies, Orzeyful significantly improved patients' ability to stay awake compared with placebo. The therapy also reduced cataplexy, sleep paralysis, hallucinations and disrupted night-time sleep. The most common adverse events included insomnia, increased urinary frequency, urinary urgency and increased salivation. "The FDA approval of Orzeyful marks a new chapter for the narcolepsy type 1 community, as we introduce an entirely new class of medicine that will potentially redefine how this disease is managed and how people feel on treatment," said Julie Kim, President and Chief Executive Officer, Takeda. The company expects to launch Orzeyful in the US in November, subject to scheduling by the Drug Enforcement Administration. Further approvals. The FDA's decision follows Orzeyful's clearance in China last month for adults and adolescents aged 16 years and older. The therapy also remains under review in Japan, while Takeda plans to file for approval in Europe later this year. Although Takeda is first to market, competition is already building. Irish biopharmaceutical company Alkermes is progressing alixorexton through phase 3 trials, while Eli Lilly's cleminorexton and Eisai's ledasorexton are both in phase 2 development. Brain health company Lundbeck is also developing Lu AH69593, which is in phase 1b trials. Press play to listen to this content
Eisai reports Leqembi first-quarter global sales. July 29, 2026 at 10:09 AM UTC - By FilingReader AI Eisai announced that global sales revenue for its anti-amyloid beta antibody Leqembi reached 293 billion yen on a pre-audit basis for the first quarter of fiscal year 2026, covering the period from April 1 to June 30, 2026. This figure compares to sales of 231 billion yen in the same period of the previous year. Breaking down the performance by major countries, sales reached 154 billion yen in the United States, 61 billion yen in Japan, and 48 billion yen in China. In the corresponding period of the previous year, regional sales stood at 91 billion yen in the United States, 55 billion yen in Japan, and 77 billion yen in China. This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact [email protected]
Pfizer, Eisai partner to co-promote Nurtec in Japan. On Jul 29, 2026 Pfizer Japan Inc. and Eisai Co., Ltd. have announced a new collaboration to co-promote the migraine treatment Nurtec OD Tablet 75mg (rimegepant sulfate hydrate) across Japan beginning September 1, 2026. The agreement is designed to expand awareness of the appropriate use of Nurtec among healthcare professionals and improve access to treatment information for patients living with migraine. While both companies will jointly provide medical information to healthcare institutions nationwide, Pfizer will continue to oversee the drug's development, manufacturing, distribution, and commercialization. Nurtec is an oral calcitonin gene-related peptide (CGRP) receptor antagonist approved for both the acute treatment of migraine attacks and the preventive treatment of migraine. The dual indication makes it one of the few oral therapies that can address both immediate symptom relief and long-term prevention. Under the co-promotion arrangement, Pfizer and Eisai will combine their respective strengths to support the broader adoption of Nurtec in clinical practice. Pfizer, as the product's marketing authorization holder, brings its expertise in developing and commercializing innovative medicines, while Eisai contributes its established presence in neurology, one of the company's strategic therapeutic focus areas. The companies said the collaboration is intended to accelerate the delivery of accurate and timely medical information to physicians and healthcare providers. By leveraging their combined healthcare networks, they aim to ensure that patients who may benefit from Nurtec have greater access to appropriate treatment options. Migraine is a chronic neurological disorder that affects millions of people worldwide and is often accompanied by severe headaches, nausea, sensitivity to light, and sensitivity to sound. Frequent migraine attacks can significantly interfere with work, education, family responsibilities, and overall quality of life. Despite advances in treatment, many patients continue to experience inadequate symptom control or remain undiagnosed and undertreated. With migraine placing a substantial burden on both patients and healthcare systems, the companies believe wider awareness of effective treatment options could help improve disease management and patient outcomes. Pfizer and Eisai said the partnership reflects their shared commitment to supporting people living with migraine by promoting the appropriate use of Nurtec. Through the expanded educational and promotional efforts, the companies aim to help more patients receive timely treatment, reduce the impact of migraine attacks, and regain their everyday lives.
Pfizer and Eisai to co-promote migraine medication in Japan. Pfizer Japan Inc. and Eisai Co., Ltd. have announced a collaboration to co-promote the oral calcitonin gene-related peptide (CGRP) receptor antagonist Nurtec(R) OD Tablet 75mg in Japan, beginning September 1, 2026. The medication, known generically as rimegepant sulfate hydrate, is designed for both acute treatment and prophylaxis of migraine. The partnership aims to enhance the dissemination of information regarding the appropriate use of Nurtec in treating migraine, a neurological disorder affecting approximately 8.4% of Japan's adult population. Pfizer will manage the development, manufacturing, distribution, and commercialization of Nurtec, while both companies will provide usage information to medical institutions. Migraine is a prevalent condition characterized by moderate-to-severe headaches and symptoms such as nausea, vomiting, and sensitivity to light and sound. The disorder significantly impacts daily life, with women aged 20-40 being the most affected demographic in Japan. Through this collaboration, Pfizer and Eisai intend to leverage their expertise and healthcare networks to promote the appropriate use of Nurtec, aiming to improve the quality of life for patients suffering from migraines. The initiative underscores the companies' commitment to addressing unmet medical needs and enhancing patient care in the neurology sector.
Eisai advances cold-chain pharma packaging capacity in UK. Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company. - Never miss a story with notifications - Browse free from any location or device. Media Packs Expand Your Reach With Its Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results! - Book a Conference Call